	US 11,732,013 B2
	Astexin peptides
A. James Link, Belle Meade, NJ (US); and Mikhail O. Maksimov, Princeton, NJ (US)
Assigned to THE TRUSTEES OF PRINCETON UNIVERSITY, Princeton, NJ (US)
Filed by The Trustees of Princeton University, Princeton, NJ (US)
Filed on Dec. 21, 2020, as Appl. No. 17/128,632.
Application 17/128,632 is a division of application No. 16/057,292, filed on Aug. 7, 2018.
Application 16/057,292 is a continuation of application No. 14/424,617, granted, now 10,072,048, issued on Sep. 11, 2018, previously published as PCT/US2013/057203, filed on Aug. 29, 2013.
Claims priority of provisional application 61/695,772, filed on Aug. 31, 2012.
Claims priority of provisional application 61/839,493, filed on Jun. 26, 2013.
Prior Publication US 2021/0107950 A1, Apr. 15, 2021
Int. Cl. C07K 14/195 (2006.01); A01N 63/50 (2020.01); A62D 3/33 (2007.01); C02F 1/28 (2023.01); A62D 101/43 (2007.01); C02F 101/20 (2006.01)

CPC C07K 14/195 (2013.01) [A01N 63/50 (2020.01); A62D 3/33 (2013.01); C02F 1/286 (2013.01); A62D 2101/43 (2013.01); C02F 2101/20 (2013.01)]

18 Claims

1. A substantially purified Astexin-3 peptide comprising the amino acid sequence GPTPMVGLDSVSGQYWDQHAPLAD (SEQ ID NO:7); wherein the glycine residue (G) at position 1 is covalently bound to the aspartic acid residue (D) at position 9, thereby generating a lassoed peptide.